John Lunger
2019
In 2019, John Lunger earned a total compensation of $932.6K as Chief Operating Officer at Adaptimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $94,542 |
|---|---|
| Option Awards | $435,546 |
| Salary | $366,867 |
| Other | $35,655 |
| Total | $932,610 |
Lunger received $435.5K in option awards, accounting for 47% of the total pay in 2019.
Lunger also received $94.5K in non-equity incentive plan, $366.9K in salary and $35.7K in other compensation.
Rankings
In 2019, John Lunger's compensation ranked 9,600th out of 13,971 executives tracked by ExecPay. In other words, Lunger earned more than 31.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,600 out of 13,971 | 31st |
Division Manufacturing | 3,864 out of 5,701 | 32nd |
Major group Chemicals And Allied Products | 1,471 out of 2,200 | 33rd |
Industry group Drugs | 1,257 out of 1,886 | 33rd |
Industry Biological Products, Except Diagnostic Substances | 280 out of 389 | 28th |
Source: SEC filing on April 21, 2022.
Lunger's colleagues
We found four more compensation records of executives who worked with John Lunger at Adaptimmune Therapeutics in 2019.